Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Anti-TB Drug Disrupted by Botanical Supplement, Can Lead to Development of Disease

By University of Missouri - Columbia | October 12, 2016

Sutherlandia is a supplement commonly taken in Africa to fight symptoms of infection and some chronic diseases, such as diabetes, but MU researchers found it may disrupt anti-tuberculosis drugs. Source: University of Missouri

 Botanical supplements are used by people around the world to treat a wide range of physical and mental ailments. Some of these botanical supplements have high levels of antioxidants, which may have some positive health effects for certain conditions. However, a new study from the University of Missouri in partnership with scientists in Africa has uncovered evidence that these supplements and their antioxidants may reduce the effectiveness of prescription medications. The researchers examined the effects of a widely used African botanical supplement, called Sutherlandia, and found that it may disrupt the effectiveness of a common anti-tuberculosis drug. This could lead to the development of active tuberculosis and perhaps drug resistant forms of the pathogen in some patients.

For the study, William Folk, a professor of biochemistry in the University of Missouri School of Medicine and College of Agriculture, Food and Natural Resources, and his colleagues monitored South African patients who were taking either Sutherlandia or a placebo, along with the world-standard anti-tuberculosis drug, isoniazid. Sutherlandia is a supplement commonly taken in Africa to fight symptoms of infection and some chronic diseases, such as diabetes. The researchers observed that several patients taking the Sutherlandia supplement developed active tuberculosis despite taking Isoniazid.

“We believe that the antioxidants in Sutherlandia can directly disrupt how Isoniazid functions within the body to prevent tuberculosis,” Folk said. “Isoniazid is very reliable in preventing the active form of this potentially deadly microbe, which is present in nearly one-third of all humans, but if individuals concurrently take a botanical supplement, they could undo the good that the scientifically proven drug is accomplishing. More than one-third of the world’s population is susceptible to active tuberculosis, so it is unfortunate that Sutherlandia, which traditionally is taken to prevent or treat infections, can actually cause them to develop the disease, and perhaps also cause the microbe to become a drug-resistant ‘super bug.’”

Folk says this finding could apply to many different botanical supplements and many different medications, including cancer-fighting drugs. He says it is important for future research to examine potential interactions between drugs and antioxidant-laden supplements.

“With so many people around the world turning to botanical supplements to help with a wide range of health issues, it is vital that we explore how these supplements interact with established medical drugs,” Folk said. “Many drugs use pathways that could be disrupted by antioxidants, so we need for physicians to better advise their patients. Many physicians do not know everything that their patients take, so it is important for people to inform their physicians, and for physicians to ask, so they can better advise their patients what is best for their health.”


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE